Notably, concurrent application of CDK4/6i and ICB does not yield tumor regression and showed limited anti‐tumor effect in preclinical models.[17, 18] Tumor regression is observed only with sequential treatment, where CDK4/6i abemaciclib is administered first, followed by ICB. The gene discussed is CDK4; the disease is neoplasm.